Cost‐efectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV

Página do item simplificado
dc.contributor.authorStefen, Ricardo E.
dc.contributor.authorPinto, Márcia
dc.contributor.authorKritski, Afranio
dc.contributor.authorTrajman, Anete
dc.date.accessioned2024-10-23T17:04:48Z
dc.date.available2024-10-23T17:04:48Z
dc.date.issued2020
dc.description.abstractTuberculosis is the leading cause of death among people living with HIV (PLH). Preventive tuberculosis therapy reduces mortality in PLH, especially in those with a positive tuberculin skin test (TST). New, more specifc technologies for detecting latent tuberculosis infection (LTBI) are now commercially available. We sought to analyse the cost-efectiveness of four diferent strategies for the diagnosis of LTBI in PLH in Brazil, from the Brazilian public health care system perspective. We developed a Markov state-transition model comparing four strategies for the diagnosis of LTBI over 20 years. The strategies consisted of TST with the currently used protein purifed derivative (PPD RT 23), two novel skin tests using recombinant allergens (Diaskintest [Generium Pharmaceutical, Moscow, Russia] and EC [Zhifei Longcom Biologic Pharmacy Co., Anhui, China]), and the QuantiFERON-TB-Gold-Plus (Qiagen, Hilden, Germany). The main outcome was cost (in 2020 US dollars) per quality-adjusted life years (QALY). For the base case scenario, the Diaskintest was dominant over all other examined strategies. The cost saving estimate per QALY was US $1375. In sensitivity analyses, the Diaskintest and other newer tests remained cost-saving compared to TST. For PLH, TST could be replaced by more specifc tests in Brazil, considering the current national recommendations.
dc.identifier.citationSteffen RE, Pinto M, Kritski A, Trajman A. Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Sci Rep. 2020 Dec 11;10(1):21823. doi: 10.1038/s41598-020-78737-w.
dc.identifier.otherDOI: 10.1038/s41598-020-78737-w.
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/526
dc.language.isoen
dc.publisherScientifc Reports
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectBrazil / epidemiologyen
dc.subjectCosts and Cost Analysisen
dc.subjectFemaleen
dc.subjectHIV Infections* / diagnosisen
dc.subjectHIV Infections* / drug therapyen
dc.subjectHIV Infections* / economicsen
dc.subjectHIV Infections* / epidemiologyen
dc.subjectHIV-1*en
dc.subjectHumansen
dc.subjectLatent Tuberculosis* / diagnosisen
dc.subjectLatent Tuberculosis* / drug therapyen
dc.subjectLatent Tuberculosis* / economicsen
dc.subjectLatent Tuberculosis* / epidemiologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMycobacterium tuberculosis*en
dc.titleCost‐efectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Steffen RE et al_ Scientific Reports.pdf
Tamanho:
1.99 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente